Treosulfan-based conditioning before hematopoietic SCT: more than a BU look-alike (Q37863461)

24 August 2017

1 reference

title

Treosulfan-based conditioning before hematopoietic SCT: more than a BU look-alike (English)

1 reference

24 August 2017

I Danylesko

1

1 reference

24 August 2017

A Shimoni

series ordinal

2

1 reference

24 August 2017

A Nagler

series ordinal

3

1 reference

24 August 2017

language of work or name

English

0 references

publication date

11 April 2011

1 reference

Bone Marrow Transplantation

24 August 2017

published in

1 reference

24 August 2017

volume

47

1 reference

24 August 2017

issue

1

1 reference

24 August 2017

page(s)

5-14

1 reference

Harnessing graft-versus-malignancy: non-myeloablative preparative regimens for allogeneic haematopoietic transplantation, an evolving strategy for adoptive immunotherapy

24 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.88

Defining the intensity of conditioning regimens: working definitions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.88

Reduced mortality after allogeneic hematopoietic-cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.88

DNA alkylation and interstrand cross-linking by treosulfan

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.88

Combination chemotherapy for choroidal melanoma: ex vivo sensitivity to treosulfan with gemcitabine or cytosine arabinoside

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.88

Potentiation of treosulfan toxicity by the glutathione-depleting agent buthionine sulfoximine in human malignant glioma cells: the role of bcl-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.88

Treosulfan as an effective second-line therapy in ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.88

Cytotoxic effects of treosulfan and busulfan against leukemic cells of pediatric patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.88

Antileukaemic activity of treosulfan in xenografted human acute lymphoblastic leukaemias (ALL).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.88

Treosulfan-induced apoptosis in acute myeloid leukemia cells is accompanied by translocation of protein kinase C delta and enhanced by bryostatin-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.88

Treosulfan is an effective inducer of cell death in myeloma cell lines and primary myeloma cells from patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.88

Dose-escalated treosulphan in combination with cyclophosphamide as a new preparative regimen for allogeneic haematopoietic stem cell transplantation in patients with an increased risk for regimen-related complications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.88

Rationale for combination therapy of chronic myelogenous leukaemia with imatinib and irradiation or alkylating agents: implications for pretransplant conditioning

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.88

Addition of treosulfan to a nonmyeloablative conditioning regimen results in enhanced chimerism and immunologic tolerance in an experimental allogeneic bone marrow transplant model

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.88

Childhood all blasts retain phenotypic and genotypic characteristics upon long-term serial passage in NOD/SCID mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.88

Myeloablative and immunosuppressive properties of treosulfan in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.88

Towards a myeloablative regimen with clinical potential: I. Treosulfan conditioning and bone marrow transplantation allow induction of donor-specific tolerance for skin grafts across full MHC barriers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.88

Toward a myeloablative regimen with clinical potential: II. Treosulfan induces specific skin graft tolerance across haploidentical MHC barriers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.88

The Pathophysiology of Acute Graft-versus-Host Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.88

Cytokines, viruses, and graft-versus-host disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.88

Progress in CLL, chemotherapy, antibodies and transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.88

A fludarabine-based dose-reduced conditioning regimen followed by allogeneic stem cell transplantation from related or unrelated donors in patients with myelodysplastic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.88

Treosulfan and fludarabine: a new toxicity-reduced conditioning regimen for allogeneic hematopoietic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.88

Fludarabine and treosulfan: a novel modified myeloablative regimen for allogeneic hematopoietic stem-cell transplantation with effective antileukemia activity in patients with acute myeloid leukemia and myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.88

Reduced-toxicity conditioning with treosulfan, fludarabine and ATG as preparative regimen for allogeneic stem cell transplantation (alloSCT) in elderly patients with secondary acute myeloid leukemia (sAML) or myelodysplastic syndrome (MDS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.88

Allogeneic hematopoietic stem-cell transplantation in patients with hematologic malignancies after dose-escalated treosulfan/fludarabine conditioning.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.88

Conditioning with treosulfan and fludarabine followed by allogeneic hematopoietic cell transplantation for high-risk hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.88

Treosulfan and fludarabine low-toxicity conditioning for allogeneic haematopoietic stem cell transplantation in chronic myeloid leukaemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.88

Reduced-toxicity conditioning with fludarabine and treosulfan prior to allogeneic stem cell transplantation in multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.88

Allogeneic hematopoietic stem-cell transplantation in AML and MDS using myeloablative versus reduced-intensity conditioning: the role of dose intensity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.88

Reduced-intensity conditioning regimen workshop: defining the dose spectrum. Report of a workshop convened by the center for international blood and marrow transplant research

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.88

Dose-reduced conditioning for allografting in 44 patients with chronic myeloid leukaemia: a retrospective analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.88

Acute left ventricular failure following melphalan and fludarabine conditioning

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.88

Reduced intensity conditioning (RIC) haematopoietic cell transplants in elderly patients with AML.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.88

Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.88

Allogeneic hematopoietic transplantation for acute and chronic myeloid leukemia: non-myeloablative preparative regimens and induction of the graft-versus-leukemia effect

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.88

Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.88

Allogeneic stem cell transplantation for myelodysplastic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.88

Reduced-intensity conditioning followed by allogeneic hematopoietic cell transplantation for adult patients with myelodysplastic syndrome and myeloproliferative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.88

Treosulfan/fludarabine as an allogeneic hematopoietic stem cell transplant conditioning regimen for high-risk patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.88

Treosulfan-containing regimens achieve high rates of engraftment associated with low transplant morbidity and mortality in children with non-malignant disease and significant co-morbidities.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.88

Results of minimally toxic nonmyeloablative transplantation in patients with sickle cell anemia and beta-thalassemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.88

The role of reduced intensity preparative regimens in patients with thalassemia given hematopoietic transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.88

High-dose cyclophosphamide for autoimmunity and alloimmunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.88

Population pharmacokinetics of melphalan in paediatric blood or marrow transplant recipients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.88

Pharmacokinetics of high-dose chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.88

[Interstitial pneumopathies caused by busulfan. Histologic, developmental and bronchoalveolar lavage analysis of 3 cases].

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.88

Prospective oral mucositis audit: oral mucositis in patients receiving high-dose melphalan or BEAM conditioning chemotherapy--European Blood and Marrow Transplantation Mucositis Advisory Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.88

Busulphan and bone marrow depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.88

Early detection of BCR-ABL transcripts by quantitative reverse transcriptase-polymerase chain reaction predicts outcome after allogeneic stem cell transplantation for chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.88

Clinical pharmacokinetics of intravenous treosulfan in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.88

7 January 2021

Epoxide formation from (2S,3S)-threitol 1,4-bismethanesulfonate. Preparation and biological activity of (2S,3S)-1,2-epoxy-3,4-butanediol 4-methanesulfonate

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.88

7 January 2021

Treosulfan is an effective alkylating cytostatic for malignant melanoma in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.88

7 January 2021

Intravenous treosulfan versus intravenous treosulfan plus cisplatinum in advanced ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.88

7 January 2021

Cytotoxicity of treosulfan and busulfan on pediatric tumor cell lines

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.88

7 January 2021

Retrospective analysis of treosulfan-based conditioning in comparison with standard conditioning in patients with myelodysplastic syndrome

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.88

7 January 2021

Allogeneic peripheral blood stem cell transplantation using a fludarabine-based low intensity conditioning regimen for malignant lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.88

7 January 2021

Improved outcome of allogeneic transplantation in high-risk multiple myeloma patients after nonmyeloablative conditioning

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.88

7 January 2021

Melphalan-associated pulmonary toxicity following high-dose therapy with autologous hematopoietic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.88

7 January 2021

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.88

7 January 2021

Reduced-intensity conditioning for myeloma: lower nonrelapse mortality but higher relapse rates compared with myeloablative conditioning

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.88

7 January 2021

Analysis of outcome following allogeneic haemopoietic stem cell transplantation for myeloma using myeloablative conditioning--evidence for a superior outcome using melphalan combined with total body irradiation

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.88

7 January 2021

Allogeneic hematopoietic stem-cell transplantation for patients 50 years or older with myelodysplastic syndromes or secondary acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.88

7 January 2021

Pharmacokinetic and metabolic studies of high-dose busulphan in adults

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.88

7 January 2021

Busulfan disposition and hepatic veno-occlusive disease in children undergoing bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.88

7 January 2021

Identifiers

DOI

10.1038/BMT.2011.88

1 reference

Dimensions Publication ID

24 August 2017

1049674859

0 references

1 reference